Medicare-negotiated drug prices to halve out-of-pocket costs next year: report
Source: SeekingAlpha
2025-12-18 12:30:35 ET
More on Pfizer, Johnson & Johnson, etc.
- Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization
- Pfizer: Ignoring The Dead Cat Bounce
- Pfizer: 2026 Feels Like Another Lost Year After Yesterday's Guidance Update
- Merck raised to Outperform at BMO on readiness for Keytruda patent cliff
- J&J wins FDA nod for Rybrevant injectable in lung cancer
Read the full article on Seeking Alpha
For further details see:
Medicare-negotiated drug prices to halve out-of-pocket costs next year: report
Novartis AG
NASDAQ: NVS
NVS Trading
-1.36% G/L:
$143.37 Last:
954,184 Volume:
$144.01 Open:
NVS Latest News
February 24, 2026 04:52:00 pm
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
NVS Stock Data
$303,205,301,793
1,889,070,162
N/A
868
N/A
Pharmaceuticals
Healthcare
CH
Basel
